/PRNewswire/ SturdyAI, a leading developer of AI-powered Customer Intelligence Solutions that create more engaging, profitable, and successful customer.
Sustainable living without giving up on urban comforts, a new hardcover book published by Stardom Books, to counter urbanization with the 7 strands of sustainability
Share Article
Integrating the seven strands of sustainability - Air, Water, Soil, Food, Energy, Shelter and People into an all-inclusive “RURBAN” commune, leading to revival of human well-being and bringing a meaningful change in Social, Economic, Political and Environmental situations, all over the world - in a new book by Rajendra Kumar, published by Stardom Books.
Blue Dharma: A Responsibility Called Earth
I believe that fresh air, clean water, nutritious food, safe shelter, and a great community. are the real luxuries today
Following the completion of the spin-off of the Upjohn Business
(4) in the fourth quarter of 2020, Pfizer now operates as a focused innovative biopharmaceutical company engaged in the discovery, development, manufacturing, marketing, sales and distribution of biopharmaceutical products worldwide.
Revenues and expenses associated with the Upjohn Business
(4) for first-quarter 2020 have been recategorized as discontinued operations and excluded from Adjusted
(2) results. Pfizer’s Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, which had been reported within the results of the Upjohn Business
(4) in the first three quarters of 2020
, is now included within the Hospital therapeutic area for all periods presented.
5%
Below are specific updates on pipeline assets since our previous earnings announcement on October 27, 2020: Abrocitinib (PF-04965842) In November 2020, Pfizer announced positive top-line results from the fifth Phase 3 trial of abrocitinib, JADE REGIMEN, a 52-week study which investigated abrocitinib in patients 12 and older with moderate to severe atopic dermatitis (AD) following response to initial open label induction treatment with abrocitinib 200 mg. Patients were randomized into one of three arms: 200 mg, 100 mg or placebo. Both doses of abrocitinib met the primary endpoint, resulting in significantly fewer patients experiencing a loss of response requiring rescue treatment compared to those randomized to placebo. Both doses also met the key secondary endpoint of a larger percentage of patients maintaining an Investigator’s Global Assessment (IGA) response of clear or almost clear relative to placebo.